In vitro evaluation of a hybrid drug delivery nanosystem for fibrosis prevention in cell therapy for Type 1 diabetes.
Claire RennieYanan HuangPrakriti SiwakotiZiqing DuMatthew PadulaGuochen BaoBernard Edward TuchXiaoxue XuLana McClementsPublished in: Nanomedicine (London, England) (2023)
Background: Implantation of insulin-secreting cells has been trialed as a treatment for Type 1 diabetes mellitus; however, the host immunogenic response limits their effectiveness. Methodology: The authors developed a core-shell nanostructure of upconversion nanoparticle-mesoporous silica for controlled local delivery of an immunomodulatory agent, MCC950, using near-infrared light and validated it in in vitro models of fibrosis. Results: The individual components of the nanosystem did not affect the proliferation of insulin-secreting cells, unlike fibroblast proliferation (p < 0.01). The nanosystem is effective at releasing MCC950 and preventing fibroblast differentiation (p < 0.01), inflammation (IL-6 expression; p < 0.05) and monocyte adhesion (p < 0.01). Conclusion: This MCC950-loaded nanomedicine system could be used in the future together with insulin-secreting cell implants to increase their longevity as a curative treatment for Type 1 diabetes mellitus.
Keyphrases
- type diabetes
- glycemic control
- drug delivery
- induced apoptosis
- signaling pathway
- cancer therapy
- cell cycle arrest
- single cell
- oxidative stress
- cell therapy
- systematic review
- randomized controlled trial
- poor prognosis
- photodynamic therapy
- dendritic cells
- cardiovascular disease
- escherichia coli
- adipose tissue
- skeletal muscle
- cystic fibrosis
- replacement therapy
- drug release